Go Pro
OTCMKTS:HLUYY

H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis

H. Lundbeck A/S logo
$22.00 -0.01 (-0.02%)
As of 08/9/2022

About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)

Key Stats

Today's Range
$22.00
▼
$24.00
50-Day Range
$22.00
▼
$22.00
52-Week Range
$10.00
▼
$31.55
Volume
7,500 shs
Average Volume
1,758 shs
Market Capitalization
$21.91 billion
P/E Ratio
25.00
Dividend Yield
0.91%
Price Target
N/A
Consensus Rating
N/A

Company Overview

H. Lundbeck A/S is a Denmark-based pharmaceutical company focused on developing and commercializing treatments for disorders of the brain. Its research and product activities primarily address psychiatry and neurology, including depression, schizophrenia, bipolar disorder, migraine, epilepsy and other conditions affecting the central nervous system.

The company’s medicines include Trintellix (vortioxetine) for major depressive disorder, Rexulti (brexpiprazole) for certain psychiatric conditions, Vyepti (eptinezumab) for migraine prevention, and therapies such as Sabril and Onfi for seizure-related disorders. Lundbeck also develops pipeline treatments through internal research and collaborations with other pharmaceutical companies.

Founded in 1915 by Hans Lundbeck, the company initially operated as a trading business before developing into a specialized pharmaceutical manufacturer. Lundbeck is headquartered in Valby, Denmark, and serves patients and healthcare providers through commercial operations and partnerships across international markets, including Europe, North America and other regions. Its business is centered on advancing therapies for people living with neurological and psychiatric diseases.

AI Generated. May Contain Errors.

Receive HLUYY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HLUYY Stock News Headlines

H LUNDBECK A/S A
H LUNDBECK A/S B
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
H. Lundbeck A/SEO-Medium-Term Nts 2025(25/29) Bond
H. Lundbeck A/S Cl B
See More Headlines

HLUYY Stock Analysis - Frequently Asked Questions

H. Lundbeck A/S's stock was trading at $22.00 at the beginning of 2026. Since then, HLUYY shares have increased by 0.0% and is now trading at $22.00.

H. Lundbeck A/S (OTCMKTS:HLUYY) posted its quarterly earnings data on Wednesday, November, 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.16. The firm had revenue of $547.05 million for the quarter, compared to analysts' expectations of $514.82 million. H. Lundbeck A/S had a net margin of 6.74% and a trailing twelve-month return on equity of 13.74%.

The following companies are subsidiaries of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/04/2015
Today
10/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:HLUYY
CIK
N/A
Employees
5,348
Year Founded
1915

Profitability

EPS (Trailing Twelve Months)
$0.88
Trailing P/E Ratio
25.00
Forward P/E Ratio
10.48
P/E Growth
N/A
Net Income
$209.69 million
Net Margins
6.74%
Pretax Margin
7.83%
Return on Equity
13.74%
Return on Assets
7.16%

Debt

Debt-to-Equity Ratio
0.32
Current Ratio
1.15
Quick Ratio
0.71

Sales & Book Value

Annual Sales
$2.59 billion
Price / Sales
8.45
Cash Flow
$3.36 per share
Price / Cash Flow
6.54
Book Value
$14.60 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
995,741,000
Free Float
N/A
Market Cap
$21.91 billion
Optionable
Not Optionable
Beta
0.68

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (OTCMKTS:HLUYY) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners